Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic agents have become a standard strategy for advanced hepatocellular carcinoma (HCC). There remains an urgent need for effective biomarkers to guide treatment, with C-reactive protein and alpha-fetoprotein in immunotherapy (CRAFITY) scores and cytokine levels representing promising candidates.

Objectives

We aimed to assess the efficacy, safety, and potential biomarkers of anlotinib plus TQB2450 in patients with advanced HCC.

Design

This study was a single-arm, phase Ib trial. Twenty-five patients with advanced HCC were enrolled.

Methods

Patients received an intravenous infusion of TQB2450 (1200 mg, on Day 1) and oral administration of anlotinib (initiated at 10 mg, once a day, from Day 1

SUBMITTER: Gong C 

PROVIDER: S-EPMC12743843 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature